AR092991A1 - Combinacion de un derivado de a 6-oxo-1,6-dihidro-piridazina que tiene actividad anticancer con un inhibidor de proteinquinasa activada por mitogenos (mek) - Google Patents
Combinacion de un derivado de a 6-oxo-1,6-dihidro-piridazina que tiene actividad anticancer con un inhibidor de proteinquinasa activada por mitogenos (mek)Info
- Publication number
- AR092991A1 AR092991A1 ARP130103703A ARP130103703A AR092991A1 AR 092991 A1 AR092991 A1 AR 092991A1 AR P130103703 A ARP130103703 A AR P130103703A AR P130103703 A ARP130103703 A AR P130103703A AR 092991 A1 AR092991 A1 AR 092991A1
- Authority
- AR
- Argentina
- Prior art keywords
- oxo
- proteinquinase
- mitogenos
- piridazina
- dihidro
- Prior art date
Links
- 230000001093 anti-cancer Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- VIUAUNHCRHHYNE-JTQLQIEISA-N N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)-4-pyridinecarboxamide Chemical compound OC[C@@H](O)CNC(=O)C1=CC=NC=C1NC1=CC=C(I)C=C1F VIUAUNHCRHHYNE-JTQLQIEISA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- AHYMHWXQRWRBKT-UHFFFAOYSA-N tepotinib Chemical compound C1CN(C)CCC1COC1=CN=C(C=2C=C(CN3C(C=CC(=N3)C=3C=C(C=CC=3)C#N)=O)C=CC=2)N=C1 AHYMHWXQRWRBKT-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Abstract
Una composición farmacéutica que comprende 3-(1-{3-[5-(1-metil-piperidin-4-ilmetoxi)-pirimidin-2-il]-bencil)-6-oxo-1,6-dihidro-piridazin-3-il)-benzonitrilo o una de sus sales y/o solvatos farmacéuticamente aceptables y N-((S)-2,3-dihidroxi-propil)-3-(2-fluoro-4-yodo-fenilamino)-isonicotinamida o una de sus sales y/o solvatos farmacéuticamente aceptables.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12007039 | 2012-10-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR092991A1 true AR092991A1 (es) | 2015-05-13 |
Family
ID=47048932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130103703A AR092991A1 (es) | 2012-10-11 | 2013-10-11 | Combinacion de un derivado de a 6-oxo-1,6-dihidro-piridazina que tiene actividad anticancer con un inhibidor de proteinquinasa activada por mitogenos (mek) |
Country Status (17)
Country | Link |
---|---|
US (1) | US20150297594A1 (es) |
EP (1) | EP2906294B1 (es) |
JP (1) | JP2015536910A (es) |
KR (1) | KR102157501B1 (es) |
CN (1) | CN104703655A (es) |
AR (1) | AR092991A1 (es) |
AU (1) | AU2013329865B2 (es) |
BR (1) | BR112015007870B1 (es) |
CA (1) | CA2887628C (es) |
ES (1) | ES2679372T3 (es) |
HK (1) | HK1211255A1 (es) |
IL (1) | IL238061B (es) |
MX (1) | MX359110B (es) |
RU (1) | RU2684407C2 (es) |
SG (1) | SG11201502628SA (es) |
WO (1) | WO2014056566A1 (es) |
ZA (1) | ZA201503186B (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201704763SA (en) * | 2014-12-11 | 2017-07-28 | Merck Patent Gmbh | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative |
CN106999493A (zh) | 2014-12-12 | 2017-08-01 | 默克专利股份公司 | 具有抗癌活性的6‑氧代‑1,6‑二氢‑哒嗪衍生物与egfr抑制剂的组合 |
PE20190912A1 (es) * | 2016-10-27 | 2019-06-26 | Fujian Cosunter Pharmaceutical Co Ltd | Compuesto de piridona como inhibidor de c-met |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102007032507A1 (de) * | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
CN101653607B (zh) * | 2008-08-19 | 2013-02-13 | 鼎泓国际投资(香港)有限公司 | 含有肝细胞生长因子受体抑制剂和丝裂原细胞外激酶抑制剂的药物组合物及其用途 |
AR084216A1 (es) * | 2010-12-09 | 2013-05-02 | Sanofi Sa | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit |
-
2013
- 2013-09-13 US US14/434,926 patent/US20150297594A1/en not_active Abandoned
- 2013-09-13 SG SG11201502628SA patent/SG11201502628SA/en unknown
- 2013-09-13 EP EP13762992.9A patent/EP2906294B1/en active Active
- 2013-09-13 KR KR1020157012085A patent/KR102157501B1/ko active IP Right Grant
- 2013-09-13 CA CA2887628A patent/CA2887628C/en active Active
- 2013-09-13 CN CN201380053015.8A patent/CN104703655A/zh active Pending
- 2013-09-13 WO PCT/EP2013/002747 patent/WO2014056566A1/en active Application Filing
- 2013-09-13 BR BR112015007870-2A patent/BR112015007870B1/pt active IP Right Grant
- 2013-09-13 AU AU2013329865A patent/AU2013329865B2/en active Active
- 2013-09-13 RU RU2015117550A patent/RU2684407C2/ru active
- 2013-09-13 MX MX2015004428A patent/MX359110B/es active IP Right Grant
- 2013-09-13 JP JP2015536004A patent/JP2015536910A/ja active Pending
- 2013-09-13 ES ES13762992.9T patent/ES2679372T3/es active Active
- 2013-10-11 AR ARP130103703A patent/AR092991A1/es unknown
-
2015
- 2015-03-31 IL IL23806115A patent/IL238061B/en active IP Right Grant
- 2015-05-08 ZA ZA2015/03186A patent/ZA201503186B/en unknown
- 2015-12-07 HK HK15112009.7A patent/HK1211255A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
MX359110B (es) | 2018-09-14 |
IL238061B (en) | 2019-10-31 |
JP2015536910A (ja) | 2015-12-24 |
CA2887628C (en) | 2020-09-08 |
CA2887628A1 (en) | 2014-04-17 |
BR112015007870B1 (pt) | 2021-12-07 |
SG11201502628SA (en) | 2015-05-28 |
WO2014056566A1 (en) | 2014-04-17 |
AU2013329865B2 (en) | 2018-04-26 |
EP2906294B1 (en) | 2018-04-18 |
HK1211255A1 (en) | 2016-05-20 |
RU2015117550A (ru) | 2016-12-10 |
BR112015007870A2 (pt) | 2017-07-04 |
US20150297594A1 (en) | 2015-10-22 |
IL238061A0 (en) | 2015-05-31 |
KR20150067343A (ko) | 2015-06-17 |
ES2679372T3 (es) | 2018-08-24 |
AU2013329865A1 (en) | 2015-05-21 |
CN104703655A (zh) | 2015-06-10 |
KR102157501B1 (ko) | 2020-09-18 |
ZA201503186B (en) | 2021-09-29 |
MX2015004428A (es) | 2015-06-24 |
RU2684407C2 (ru) | 2019-04-09 |
EP2906294A1 (en) | 2015-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SV2016005277A (es) | Nanopartã�culas terapã‰uticas que comprenden un agente terapã‰utico, y mã‰todos para su elaboraciã“n y uso | |
ES2721666T3 (es) | Composición farmacéutica sólida que contiene 1-(3-(2-(1-benzotiofen-5-il)etoxi)propil)azetidin-3-ol o una sal del mismo | |
TWD181967S (zh) | 記錄媒體 | |
UY35998A (es) | 1-(3-(tert-BUTIL)1-(p-TOLIL)-1H-PIRAZOL-5-IL)-3-(4-((2-((6-ETILPIRAZIN-2-IL)AMINO)PIRIDIN-4-IL)METOXI)NAFTALEN-1-IL) UREA Y SUS SALES DERIVADAS FARMACÉUTICAMENTE ACEPTABLES, COMO INHIBIDORES DE P38 M AP QUINASA | |
CL2011000976A1 (es) | Compuestos derivados de isonicotinamida y carboxamida, antagonistas de los receptores de orexina; composicion farmaceutica que los comprende; y su uso para la prevencion de un trastorno del sueno. | |
DOP2011000249A (es) | Compuesto de anillo fusionado y su uso | |
ECSP15004234A (es) | Sales y formas sólidas de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona y composiciones que comprenden y métodos para utilizar las mismas | |
CL2015002608A1 (es) | Compuesto de amino-pirazol y usos medicinales relacionados. | |
CL2015003562A1 (es) | Inhibidores de pi3 cinasa delta y gamma selectivos duales. | |
CL2016001172A1 (es) | Nuevos inhibidores de dgat2. | |
CL2008001389A1 (es) | Panel para la construccion compuesto por un panel de material aislante que consta de medios que sobresalen prolongandose desde una cara del panel. | |
BR112015002183A2 (pt) | processos para a preparação de (s) -3- (4 - ((4- (morfolinometil) benzil) oxi) -1-oxoisoindolin-2-il) -piperidina-2,6-diona e formas farmaceuticamente aceitáveis da mesma | |
ES2869910T8 (es) | Preparación compuesta, que contiene un nuevo derivado de ácido 3-(4-(benciloxi)fenil)hex-4-inoico y otro principio activo, para prevenir o tratar enfermedades metabólicas | |
AR092991A1 (es) | Combinacion de un derivado de a 6-oxo-1,6-dihidro-piridazina que tiene actividad anticancer con un inhibidor de proteinquinasa activada por mitogenos (mek) | |
CY1122473T1 (el) | Βελτιστοποιημενο μεσαλαζiνουχο δισκιο υψηλης δοσης | |
UY37560A (es) | Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta | |
CL2017001477A1 (es) | Combinación de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anti-cáncer con un derivado de quinazolina | |
CL2017001478A1 (es) | Combinación de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anti-cáncer con un inhibidor de factor de crecimiento epidérmico (egfr) | |
CL2013000492A1 (es) | Usos terapeuticos de 1-[2-(2,4-dimetil-fenilsulfanil) fenil]piperazina y sus sales para un tratamiento a largo plazo de una enfermedad del snc que esta asociado con un ligero o con un no aumento de peso | |
CL2018001157A1 (es) | Formulación de combinación de dosis fija, eflornitina y sulindaco. | |
PH12016500948A1 (en) | Combination of a 6-oxo- 1,6-dihydro-pyridazine derivate having anti-cancer activity with gefitinib | |
AR093318A1 (es) | Un derivado de 6-oxo-1,6-dihidro-piridazina para el uso para el tratamiento de carcinoma hepatocelular (hcc) | |
AR101523A1 (es) | Compuestos para el tratamiento de condiciones asociadas con la actividad de dgat1 | |
CL2015003434A1 (es) | Composición farmacéutica, su uso y régimen de administración para contracepción a demanda. | |
BR112017012558A2 (pt) | Composições de (s)-n-(3-(6-isopropoxipiridin-3-il)-1h- indazol-5-il)-1-(2-(4-(4-(1-metil-1h-1,2,4-triazol-3-il) fenil)-3,6-diidropiridin-1(2h)-il)-2-oxoetil)-3-(metiltio) pirrolidina-3-carboxamida para preparações farmacêuticas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |